Urologic Health Raises $11 Million Seed Round to Advance Non-Invasive Bladder Diagnostics
Urologic Health Inc. raises $11 million in seed funding to develop its non-invasive bladder diagnostic technology, the niu System.
Jerusalem, 17 May, 2026 (TPS-IL) — Urologic Health Inc., a U.S.-Israeli medical device company, announced it has raised $11 million in seed financing to advance its non-invasive bladder function monitoring technology. The round was led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and other healthcare-focused backers.
The company’s niu System enables catheter-free urodynamic testing by converting bladder activity into clinically meaningful diagnostic data, aiming to improve assessment of conditions such as overactive bladder, urinary retention, incontinence, and benign prostatic hyperplasia. Proceeds will support clinical validation, FDA 510(k) regulatory efforts, product and manufacturing development, and early U.S. commercialization, including establishment of a headquarters in New Jersey.
